Literature DB >> 27524303

A strategy of designing the ligand of antibody affinity chromatography based on molecular dynamics simulation.

Lu Dai1, Weikang Li2, Fei Sun1, Baizhi Li1, Hongrui Li1, Hongxing Zhang3, Qingchuan Zheng4, Chongyang Liang5.   

Abstract

Designing affinity ligands has always been the development focus of affinity chromatography. Previous antibody affinity ligand designs were mostly based on the crystal structure of protein A (UniProt code number: P38507), and the antibody-binding domains were modified according to the properties of amino acid residues. Currently, more effective bioinformatic prediction and experimental validation has been used to improve the design of antibody affinity ligands. In the present study, the complex crystal structure (the domain D of protein A and the Fab segment of IgM, PDB code: 1DEE) was used as the model. The vital site that inhibits the binding between domain D and IgM was estimated by means of molecular dynamics (MD) simulation, then MM-GBSA calculations were used to design a mutant of domain D (K46E) for improving affinity on the above vital site. The binding analysis using Biacore showed the association and dissociation parameters of K46E mutant that were optimized with IgM. The affinity increase of K46E mutant preferred for IgM, the affinity order is K46E tetramer (KD=6.02×10(-9)M)>K46E mutant (KD=6.66×10(-8)M)>domain D (KD=2.17×10(-7)M). Similar results were obtained when the optimized ligands were immobilized to the chromatography medium. A complete designing strategy was validated in this study, which will provide a novel insight into designing new ligands of antibody affinity chromatography media.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ligand; Molecular dynamics; Staphylococcal protein A; Surface plasmon resonance

Mesh:

Substances:

Year:  2016        PMID: 27524303     DOI: 10.1016/j.chroma.2016.08.004

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  1 in total

1.  Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.

Authors:  Rui Cao; Wenping Song; Cheng Ye; Xiujun Liu; Liang Li; Yi Li; Hongjuan Yao; Xiaofei Zhou; Liang Li; Rongguang Shao
Journal:  Cancer Med       Date:  2019-01-25       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.